Goldman Sachs Maintains Neutral on Dynavax Technologies, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a Neutral rating on Dynavax Technologies (NASDAQ:DVAX) but lowers the price target from $20 to $15.

August 08, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs analyst Paul Choi maintains a Neutral rating on Dynavax Technologies but lowers the price target from $20 to $15.
The lowered price target from $20 to $15 by a major financial institution like Goldman Sachs is likely to have a negative short-term impact on Dynavax Technologies' stock price. The Neutral rating suggests no strong buy or sell recommendation, but the reduced price target indicates a less optimistic outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100